

## AroCell appoints Marianne Alksnis as Senior Sales Director

**AroCell AB (publ.) announces today that it is strengthening the company by hiring Marianne Alksnis as Senior Sales Director. Marianne will be leading Arocell's sales efforts and continue to develop the global distributor network.**

Marianne has over 20 years' experience of international business development and sales in Life science and has a broad knowledge in the global pharma and diagnostic market. She has also documented experience in direct sales and very good experience in building strong relationships with both established and new distributors.

Marianne has previously worked at Karo Pharma and Mercodia. During her time at KaroBio (now Karo Pharma), Marianne developed her business development skills by working with out-licensing. At Mercodia, Marianne was "Global Export Manager" and was responsible for sales of ELISA kits through distributors globally. Marianne's most recent employment was at Calmark Sweden AB.

"I'm looking forward to start working at Arocell in this interesting phase that the company is in," says Marianne Alksnis. "It will be exciting to contribute with my knowledge and experience in building a global company".

"I am very pleased that Marianne has chosen to start working at Arocell. Marianne has a long international experience in sales and will focus on increasing our sales and continue to develop and build up our distributor network in our various markets," says Michael Brobjer, CEO of AroCell. "With Marianne, we have now recruited three key positions who together strengthen AroCell's ability to achieve success. With these reinforcements in Regulatory, Clinical development and Sales, AroCell stands significantly stronger for future challenges," concludes Michael Brobjer.

### Contacts

---

Michael Brobjer, CEO  
Telephone: +46(0)18 50 30 20  
E-mail: [michael.brobjer@arocell.com](mailto:michael.brobjer@arocell.com)

## About AroCell

---

AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser: [Certifiedadviser@redeye.se](mailto:Certifiedadviser@redeye.se), +46 (0)8 121 576 90. For more information; [www.arocell.com](http://www.arocell.com)

## Attachments

---

[AroCell appoints Marianne Alksnis as Senior Sales Director](#)